Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

2seventy bio, Inc. - Common Stock (NQ: TSVT )

3.960 +0.270 (+7.32%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 2seventy bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Cancer Drug Trials Put On Hold After Patients Died
Recent reports from two drug companies that had been conducing separate clinical trials to evaluate cancer treatments reveal that the trials were halted due to the deaths of six participants, including... 
Via Benzinga
2seventy Bio Pauses Pediatric Blood Cancer Trial After Patient Death, Stock Plunges
2seventy Bio Inc (NASDAQ: TSVT) announced that the Phase 1 trial of the PLAT-08 study of SC-DARIC33 in Acute Myeloid Leukemia (AML), has been paused by Seattle Children's, the company's partner and... 
Via Benzinga
2seventy Bio Stock Crumbles After A Patient Dies In Its Pediatric Cancer Study
The company is investigating whether the death is tied to the experimental drug. 
Via Investor's Business Daily
2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia
From 2seventy bio, Inc.
Via Business Wire
2seventy bio: Q1 Earnings Insights
Via Benzinga
2seventy bio's Return On Capital Employed Overview
Via Benzinga
Wedbush Maintains Outperform Rating for 2seventy bio: Here's What You Need To Know
Via Benzinga
Where 2seventy bio Stands With Analysts
Via Benzinga
2seventy bio to Participate in Upcoming Investor Conference
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Presents Late-Breaking Results for SC-DARIC33, an Investigational CD33-Targeting CAR T in Pediatric and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia
From 2seventy bio
Via Business Wire
2seventy bio Presents Broad Range of New Data Highlighting Novel Approaches Across its Cell Therapies Portfolio
From 2seventy bio, Inc.
Via Business Wire
Benzinga Pro's Top 5 Stocks To Watch For Friday, May 12, 2023: CMCSA, KR, ON, TSVT, CMND
Comcast (CMCSA) - The parent company of NBCUniversal. One of Friday's most-discussed stories stemmed from a tweet by Elon Musk he had found a new exec to file the chief exec role at Twitter. 
Via Benzinga
2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting
From 2seventy bio
Via Business Wire
2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program
From 2seventy bio
Via Business Wire
2seventy bio to Report First Quarter 2023 Financial Results on May 3, 2023
From 2seventy bio, Inc.
Via Business Wire
Legend Biotech Breaks Out After Leaked Documents Show Big CAR-T Benefit
The company could have the best-in-class CAR-T drug for multiple myeloma patients. 
Via Investor's Business Daily
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
  On Monday, 147 stocks made new 52-week lows. 
Via Benzinga
2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
  During Friday's session, 149 stocks hit new 52-week lows. 
Via Benzinga
2seventy bio Announces Appointment of Wei Lin, M.D. to Board of Directors
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Participate in 43rd Annual TD Cowen Health Care Conference
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Announces Pricing of Upsized Public Offering of Common Stock
From 2seventy bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
2seventy bio Announces Proposed Public Offering of Common Stock
From 2seventy bio, Inc.
Via Business Wire
Bristol Myers-2seventy Partnered Abecma Cuts Risk Of Disease Progression, Death By 51% In Pretreated Myeloma Patients
Via Benzinga
Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study
From Bristol Myers Squibb
Via Business Wire
2seventy bio to Participate in Upcoming Investor Conferences
From 2seventy bio, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.